Press Releases

November 27, 2018
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease Read More
November 7, 2018
Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14 Read More
November 6, 2018
Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update Read More
November 6, 2018
Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200 Read More
October 22, 2018
Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week Read More
October 8, 2018
Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting Read More
September 27, 2018
Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300 Read More
September 24, 2018
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1 Read More
September 19, 2018
Protagonist Therapeutics Reports Granting of Inducement Award Read More
September 6, 2018
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300 Read More
September 6, 2018
Protagonist Therapeutics Expands Intellectual Property Portfolio Read More
August 17, 2018
Protagonist Therapeutics Reports Granting of Inducement Award Read More
August 7, 2018
Protagonist Therapeutics Reports Second Quarter 2018 Financial Results Read More
August 6, 2018
Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis Read More
August 6, 2018
Protagonist Therapeutics Secures $22 Million Equity Financing Read More
June 18, 2018
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting Read More
June 6, 2018
Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference Read More
June 1, 2018
Protagonist Therapeutics Reports Granting of Inducement Award Read More
May 24, 2018
Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer Read More
May 17, 2018
Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association Read More